Investment Remains Strong in an Adapt or Die Environment
The Automation Expenditures for Pharmaceutical and Biotech Worldwide Outlook examines the market for automation products and systems in pharmaceutical and biotech clinical trials and commercial manufacturing and the factors contributing to the growth and deployment of specific products and systems.
Automation products and systems include enterprise asset management, general motion control, LIMS, AC drives, plant asset management, PLCs, DCS, process safety systems, HMIs, field transmitters and valves, process engineering tools, real-time process optimization, and production management.
The outlook for the pharmaceutical and biotech industry in 2009 will be moderate due to a general drop in prescription drug usage, the 'Obama effect', increased use of generics, and tightening budgets. Much of the current automation deployment focuses on projects with immediate return on investments, projects that are the result of consolidation of manufacturing operations, and standardization of applications across the entire enterprise. The industry continues to attract investment capital for large mergers and acquisitions further impacting automation expenditures over the short term. However, the industry is healthy and global demand for branded, generic, and OTC drug products remains strong.
Strategic Issues
This study provides strategic market information and guidance about automation products and systems being deployed worldwide in the pharmaceutical and biotech industry. In addition to quantitative assessments, the study also identifies key strategic issues in 2009 and beyond that will have substantial impact on this market such as:
- Market potential and size for automation products and systems
- Leading and key suppliers in this vertical industry sector
- Market size in various world regions
- Strategies for suppliers and manufacturers to be successful in the rapidly changing 'adapt or die' environment of the worldwide pharmaceutical and biotech industry.
